310 related articles for article (PubMed ID: 24975889)
1. Clinical effects of the new phosphorus binder, bixalomer in hemodialysis patients switched from sevelamer hydrochloride.
Gen S; Sasaki T; Saito K; Nobe K; Nodaira Y; Ikeda N
Ther Apher Dial; 2014 Jun; 18 Suppl 2():8-12. PubMed ID: 24975889
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hyperphosphatemia with bixalomer in Japanese patients on long-term hemodialysis with gastrointestinal symptoms.
Ito K; Takeshima A; Shishido K; Wakasa M; Kumata C; Matsuzaka K; Nakajima Y; Ogata H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():19-23. PubMed ID: 24975891
[TBL] [Abstract][Full Text] [Related]
3. Effects of switching from sevelamer hydrochloride to bixalomer on laboratory parameters in hemodialysis patients.
Furukawa K; Ikawa T; Yokoi S; Yokouchi S; Kato K; Ueno M; Takahashi J
Ther Apher Dial; 2014 Jun; 18 Suppl 2():2-7. PubMed ID: 24975888
[TBL] [Abstract][Full Text] [Related]
4. Clinical experiences of bixalomer usage at our hospital.
Shima H; Makino R; Hata K; Ban A; Funao K; Sugita S; Furumitsu Y; Inoue K; Yoshimoto M; Okamura M
Ther Apher Dial; 2014 Jun; 18 Suppl 2():13-8. PubMed ID: 24975890
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding study of bixalomer in patients with chronic kidney disease on hemodialysis with hyperphosphatemia: a double-blind, randomized, placebo-controlled and sevelamer hydrochloride-controlled open-label, parallel group study.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kanoh H
Ther Apher Dial; 2014 Jun; 18 Suppl 2():24-32. PubMed ID: 24975892
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia.
Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S;
Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402
[TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy of the phosphate binders nicotinic acid and sevelamer hydrochloride in hemodialysis patients.
Ahmadi F; Shamekhi F; Lessan-Pezeshki M; Khatami MR
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):934-8. PubMed ID: 22982903
[TBL] [Abstract][Full Text] [Related]
8. Switching hemodialysis patients from sevelamer hydrochloride to bixalomer: a single-center, non-randomized analysis of efficacy and effects on gastrointestinal symptoms and metabolic acidosis.
Hatakeyama S; Murasawa H; Narita T; Oikawa M; Fujita N; Iwamura H; Mikami J; Kojima Y; Sato T; Fukushi K; Ishibashi Y; Hashimoto Y; Koie T; Saitoh H; Funyu T; Ohyama C
BMC Nephrol; 2013 Oct; 14():222. PubMed ID: 24119202
[TBL] [Abstract][Full Text] [Related]
9. Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.
Taniguchi K; Kakuta H
Eur J Pharmacol; 2015 Nov; 766():129-34. PubMed ID: 26452517
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis.
Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H
Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis.
Evenepoel P; Selgas R; Caputo F; Foggensteiner L; Heaf JG; Ortiz A; Kelly A; Chasan-Taber S; Duggal A; Fan S
Nephrol Dial Transplant; 2009 Jan; 24(1):278-85. PubMed ID: 18820280
[TBL] [Abstract][Full Text] [Related]
12. Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Kishi Y; Obara Y; Hara K; Yamashiro H; Kurosawa N; Takada D
Ther Apher Dial; 2014 Jun; 18 Suppl 1():9-13. PubMed ID: 24953760
[TBL] [Abstract][Full Text] [Related]
13. Comparison of sevelamer hydrochloride with colestimide, administered alone or in combination with calcium carbonate, in patients on hemodialysis.
Itoh K; Tanaka M; Hashiguchi J; Funakoshi S; Nakano H; Kubo H; Kono T; Uchino J; Masaki K; Date T; Shigematsu T;
Ther Apher Dial; 2008 Apr; 12(2):126-32. PubMed ID: 18387160
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Prajapati VA; Galani VJ; Shah PR
Saudi J Kidney Dis Transpl; 2014 May; 25(3):530-8. PubMed ID: 24821148
[TBL] [Abstract][Full Text] [Related]
15. A comparison of sevelamer hydrochloride with calcium acetate on biomarkers of bone turnover in hemodialysis patients.
Liu YL; Lin HH; Yu CC; Kuo HL; Yang YF; Chou CY; Lin PW; Liu JH; Liao PY; Huang CC
Ren Fail; 2006; 28(8):701-7. PubMed ID: 17162430
[TBL] [Abstract][Full Text] [Related]
16. Phosphate binders and metabolic acidosis in patients undergoing maintenance hemodialysis—sevelamer hydrochloride, calcium carbonate, and bixalomer.
Sanai T; Tada H; Ono T; Fukumitsu T
Hemodial Int; 2015 Jan; 19(1):54-9. PubMed ID: 24980286
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
18. Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis.
Goldsmith DR; Scott LJ; Cvetković RS; Plosker GL
Drugs; 2008; 68(1):85-104. PubMed ID: 18081374
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
20. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
Chudek J; Piecha G; Kokot F; Wiecek A
J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
